Vor Biopharma (VOR) EBITDA (2020 - 2026)

Vor Biopharma (VOR) has reported EBITDA for 7 consecutive years, with -$35.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 5.61% year-over-year to -$35.2 million; the TTM figure through Mar 2026 stood at -$373.5 million (down 205.78% YoY), while the FY2025 annual figure was -$371.6 million, down 206.67% from the prior year.
• EBITDA climbed to -$35.2 million in Q1 2026 per VOR's latest filing, from -$36.0 million in the prior quarter.
• Across five years, EBITDA topped out at -$21.8 million in Q2 2022 and bottomed at -$274.3 million in Q2 2025.
• Historically, EBITDA has averaged -$44.0 million across 5 years, with a median of -$30.4 million in 2023.
• Annual changes were most pronounced in 2024 — EBITDA advanced 19.26% — and 2025, when it sank 844.67%.
• Vor Biopharma's EBITDA stood at -$24.7 million in 2022, then decreased by 13.75% to -$28.1 million in 2023, then slipped by 11.33% to -$31.3 million in 2024, then retreated by 14.85% to -$36.0 million in 2025, then grew by 2.22% to -$35.2 million in 2026.
• Business Quant data shows VOR's EBITDA at -$35.2 million in Q1 2026, -$36.0 million in Q4 2025, and -$28.1 million in Q3 2025.